Chordal cutting: a new therapeutic approach for ischemic mitral regurgitation

E Messas1, J L Guerrero, M D Handschumacher

  • 1Cardiac Ultrasound Laboratory and Surgical Cardiovascular Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Circulation
|October 17, 2001
PubMed
Abstract

Insights

Cutting specific basal chordae in mitral valves effectively reduces ischemic mitral regurgitation by improving leaflet closure without causing prolapse. This minimally invasive approach shows promise for treating this heart condition.

Area of Science:

  • Cardiovascular Surgery
  • Cardiac Mechanics
  • Interventional Cardiology

Background:

  • Ischemic mitral regurgitation (MR) is linked to adverse prognosis in heart disease.
  • Leaflet tethering due to papillary muscle displacement causes MR, which is not fully addressed by annular reduction.
  • The hypothesis tested was that selective chordae cutting could reduce MR by releasing leaflet restriction.

Purpose of the Study:

  • To investigate the efficacy of cutting specific basal chordae in reducing ischemic mitral regurgitation.
  • To assess the impact of chordal cutting on mitral valve geometry and function.
  • To explore a potential minimally invasive treatment for ischemic MR.

Main Methods:

  • Experiments were conducted on 8 mitral valves, including a porcine in vitro model and 7 sheep with induced myocardial infarction.
  • Three-dimensional (3D) echocardiography was used to quantify MR and analyze 3D valve geometry in vivo.
  • Selective cutting of basal chordae was performed to release leaflet tethering.

Main Results:

  • Papillary muscle displacement caused leaflet restriction and mild-to-moderate MR in all tested valves.
  • Cutting the two central basal chordae effectively reduced MR without inducing prolapse.
  • In vivo, MR significantly decreased from 7.1±0.5 mL/beat post-infarction to 0.9±0.1 mL/beat after chordal cutting (P<0.0001).

Conclusions:

  • A minimal chordae cutting strategy can improve mitral valve coaptation and reduce ischemic MR.
  • This approach offers a potential method for future minimally invasive interventions for ischemic MR.

Related Concept Videos

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents01:17

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents01:20

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...